Smoking Cessation
Conditions
Brief summary
Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. Only two rigorous randomized controlled trials (RCTs) on the efficacy of ENDS to help smokers quit have been published so far. They have promising, yet inconclusive results, as the number of included participants were small. The safety and potential adverse effects of ENDS are also largely unknown. While the aerosol the users inhale appears safe in laboratory conditions, the difference in exposure to chemicals (such as reduction in exposure to volatile organic compounds) and effects of chemicals on the body (adverse events, improved health-related outcomes and measures of oxidative stress) between smokers who quit (with or without ENDS) and those who use ENDS for a long time have not yet been assessed in an RCT. This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals. The primary hypothesis of this trial is that providing cigarette smokers willing to quit smoking tobacco cigarettes with ENDS leads to a higher rate of smokers who quit cigarette smoking than only smoking cessation counseling with nicotine replacement therapy (NRT), which represents nowadays the standard of care. For this trial, cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. Participants in both groups will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. After 6,12, 24, 60 months, participants will be asked to come to a clinical visit.
Interventions
Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
OTHERSmoking cessation counseling
Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 60-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12, 24 and 60 months, participants will be asked to come to a clinical visit.
Sponsors
University of Lausanne
University of Geneva, Switzerland
University of Zurich
State Hospital, St. Gallen
Swiss National Science Foundation
Krebsforschung Schweiz, Bern, Switzerland
Federal Office of Public Health, Switzerland
University of Bern
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Masking description
Statisticians and laboratory personnel will be blinded to group allocation.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Informed Consent as documented by signature * Persons aged 18 or older * Currently smoking 5 or more cigarettes a day for at least 12 months * Willing to try to quit smoking within the next 3 months, * Persons providing a valid phone number, a valid email address and/or a valid postal address.
Exclusion criteria
* Known hypersensitivity or allergy to contents of the e-liquid Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected * Women who are pregnant or breast feeding * Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study * Persons having used ENDS regularly in the 3 months preceding the baseline visit * Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit * Persons who cannot attend the 6- month follow-up visit for any reason * Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validated 7-day point prevalence abstinence (1) | 6 months post quit date | Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO). |
| Validated 7-day point prevalence abstinence (1.1) | 12 months post quit date | Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO). |
| Validated 7-day point prevalence abstinence (2) | 24 months post quit date | Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO). |
| Validated 7-day point prevalence abstinence (2.1) | 60 months post quit date | Confirmation of having smoked no cigarettes in the past seven days, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Validated smoking abstinence allowing a 2-week'grace period' (1) | 12, 24 and 60 months post quit date | Smoking abstinence allowing a 2-week'grace period' after the target quit date, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO). |
| Validated smoking abstinence allowing a 2-week'grace period' (2) | 12, 24 and 60 months post quit date | Smoking abstinence allowing a 2-week'grace period' after the target quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO). |
| Self-reported smoking abstinence allowing up to 5 cigarettes | 12, 24 and 60 months post quit date | Smoking abstinence allowing up to 5 cigarettes in total after the target quit date. |
| Validated smoking abstinence allowing up to 5 cigarettes (1) | 12, 24 and 60 months post quit date | Smoking abstinence allowing up to 5 cigarettes in total after the target quit date, validated by urinary levels of anabasine. If anabasine is missing validation by exhaled carbon monoxide (CO). |
| Validated smoking abstinence allowing up to 5 cigarettes (2) | 12, 24 and 60 months post quit date | Smoking abstinence allowing up to 5 cigarettes in total after the target quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO). |
| Number of cigarettes smoked per day (CPD) | 12, 24 and 60 months post quit date | self-reported |
| Self-reported 7-day point prevalence abstinence | 12, 24 and 60 months post quit date | Self-report of having smoked no cigarettes in the past seven days. |
| Use of any other smoking cessation products (NRT, Nicotine replacement therapy) | 12, 24 and 60 months post quit date | self-reported on whether and how often they used any NRT. |
| Withdrawal | 12, 24 and 60 months post quit date | The physical signs and symptoms associated with withdrawal, measured using the Minnesota Tobacco Withdrawal Scale. The Minnesota Tobacco Withdrawal Scale measures self-reported severity of nicotine withdrawal. The measure has 15 items, with five possible responses (0-5), thus scores on the scale range from 0 to 60. |
| Nicotine dependence | 12, 24 and 60 months post quit date | Nicotine dependence measured using the Fagerström Test. The Fagerström Test for Nicotine Dependence (FTND, Heatherton TF et al., 1991) is a standard instrument for assessing the intensity of physical addiction to nicotine. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. Two items have four possible responses (0-3) and four items have two possible responses (0-1). The nicotine dependence score ranges from 0 to 10. A score between 0 and 2 is considered as a low nicotine dependence, a score between 3 to 5 is considered as a medium nicotine dependence, a score between 6 and 7 is considered as a high nicotine dependence and a score between 8 and 10 is considered as a very high nicotine dependence. |
| Health-related quality of life | 12, 24 and 60 months post quit date | Measured using the Swiss EQ-5D. The EQ-5D questionnaire is a standardized measure of health status developed by the EuroQol Group (https://euroqol.org/). EQ-5D questionnaires have five dimensions: Mobility, Self-care, Usual Activities, Pain / Discomfort, Anxiety / Depression and all dimensions are described by five problem levels corresponding to participant response choices. |
| Use of any ENDS | 12, 24 and 60 months post quit date | self-reported on whether and how often they used any ENDS |
| Report on most common adverse events using ENDS | 12, 24 and 60 months post quit date | Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of ENDS, whether or not it is considered related to the product. |
| Change in number of cigarettes smoked per day (CPD) | 12, 24 and 60 months post quit date | self-reported.Successful reduction defined as 50% reduction in CPD. |
| Continuous smoking abstinence | 12, 24 and 60 months post quit date | Self-report of having smoked no cigarettes from quit date, validated by urinary levels of anabasine. If anabasine is missing, validation by exhaled carbon monoxide (CO). |
| Continuous smoking abstinence (2) | 12, 24 and 60 months post quit date | Self-report of having smoked no cigarettes from quit date, validated by urinary levels of NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol). If NNAL is missing, validation by urinary levels of anabasine or exhaled carbon monoxide (CO). |
| Self-reported smoking abstinence allowing a 2-week'grace period' | 12, 24 and 60 months post quit date | Smoking abstinence allowing a 2-week'grace period' after the target quit date. |
Countries
Switzerland
Outcome results
None listed